Amedeo Smart

Free Medical Literature Service

 

Amedeo

Alzheimer's Disease
  Free Subscription

Articles published in
Brain
    June 2025
  1. JIANG S, Srikanth M, Serpe R, Yavari S, et al
    Early proteasome downregulation and dysfunction drive proteostasis failure in Alzheimer's disease.
    Brain. 2025 Jun 9:awaf222. doi: 10.1093.
    >> Share

  2. VELLONE D, Leon R, Goodarzi Z, Forkert ND, et al
    Mild behavioural impairment-apathy and core Alzheimer's disease cerebrospinal fluid biomarkers.
    Brain. 2025 Jun 2:awaf194. doi: 10.1093.
    >> Share

    May 2025
  3. ABDEL-HALEEM AM, Casavant E, Toth B, Teng E, et al
    CSF proteomics of semorinemab Alzheimer's disease trials identifies cell-type specific signatures.
    Brain. 2025 May 28:awaf200. doi: 10.1093.
    >> Share

  4. WISSE LEM, La Joie R
    Medial temporal lobe structural changes when Down syndrome and Alzheimer's disease collide.
    Brain. 2025 May 14:awaf176. doi: 10.1093.
    >> Share

  5. RICKENBACH C, Mallone A, Hausle L, Frei L, et al
    Altered T-cell reactivity in the early stages of Alzheimer's disease.
    Brain. 2025 May 5:awaf167. doi: 10.1093.
    >> Share

    April 2025
  6. POMARA N, Imbimbo BP
    Making a diagnosis of Alzheimer's disease in asymptomatic individuals with positive biomarkers.
    Brain. 2025 Apr 28:awaf162. doi: 10.1093.
    >> Share

  7. SHARIF SF, Guan DX, Bodnar T, Joseph JT, et al
    Neuropsychiatric symptoms and progression to pathologically confirmed Alzheimer's disease.
    Brain. 2025 Apr 25:awaf156. doi: 10.1093.
    >> Share

  8. ABANTO JT, Dwivedi AK, Imbimbo BP, Espay AJ, et al
    CSF amyloid-beta40 levels are not associated with efficacy outcomes in Alzheimer's disease trials.
    Brain. 2025 Apr 19:awaf143. doi: 10.1093.
    >> Share

  9. BUEHNER BJ, Morcillo-Nieto AO, Zsadanyi SE, Rozalem Aranha M, et al
    Medial temporal lobe atrophy in Down syndrome along the Alzheimer's disease continuum.
    Brain. 2025 Apr 17:awaf133. doi: 10.1093.
    >> Share

  10. LU K, Baker J, Nicholas JM, Street RE, et al
    Associations between accelerated forgetting, amyloid deposition and brain atrophy in older adults.
    Brain. 2025;148:1302-1315.
    >> Share

    March 2025
  11. PHILLIPS JM, Dumitrescu LC, Archer DB, Regelson AN, et al
    Novel modelling approaches to elucidate the genetic architecture of resilience to Alzheimer's disease.
    Brain. 2025 Mar 20:awaf106. doi: 10.1093.
    >> Share

    February 2025

  12. Correction to: Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparison.
    Brain. 2025 Feb 6:awaf034. doi: 10.1093.
    >> Share

  13. LIU H, Marsh TW, Shi X, Renton AE, et al
    The landscape of autosomal-dominant Alzheimer's disease: global distribution and age of onset.
    Brain. 2025 Feb 4:awaf038. doi: 10.1093.
    >> Share

  14. HUSAIN M
    Listening into hippocampal hyperexcitability in Alzheimer's disease.
    Brain. 2025;148:347-348.
    >> Share

  15. WARMENHOVEN N, Salvado G, Janelidze S, Mattsson-Carlgren N, et al
    A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests.
    Brain. 2025;148:416-431.
    >> Share

    January 2025
  16. FERNANDEZ ARIAS J, Brum WS, Salvado G, Therriault J, et al
    Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer's disease spectrum.
    Brain. 2025 Jan 29:awaf033. doi: 10.1093.
    >> Share

  17. CHAUVEAU L, Landeau B, Dautricourt S, Turpin AL, et al
    Anterior-temporal network hyperconnectivity is key to Alzheimer's disease: from ageing to dementia.
    Brain. 2025 Jan 15:awaf008. doi: 10.1093.
    >> Share

  18. GRAHAM AC, Bellou E, Harwood JC, Yaman U, et al
    Human longevity and Alzheimer's disease variants act via microglia and oligodendrocyte gene networks.
    Brain. 2025 Jan 9:awae339. doi: 10.1093.
    >> Share

  19. VAN DER FLIER WM, Heneka MT
    Zooming in on brain inflammation in Alzheimer's disease.
    Brain. 2025;148:1-2.
    >> Share

  20. TIAN F, Wang Y, Qian ZM, Ran S, et al
    Plasma metabolomic signature of healthy lifestyle, structural brain reserve and risk of dementia.
    Brain. 2025;148:143-153.
    >> Share

    December 2024
  21. PILOTTO A, Quaresima V, Trasciatti C, Tolassi C, et al
    Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparison.
    Brain. 2024 Dec 16:awae368. doi: 10.1093.
    >> Share

  22. WANG D, Honnorat N, Toledo JB, Li K, et al
    Deep learning reveals pathology-confirmed neuroimaging signatures in Alzheimer's, vascular and Lewy body dementias.
    Brain. 2024 Dec 9:awae388. doi: 10.1093.
    >> Share

  23. LEE SH, Bae EJ, Perez-Acuna D, Jung MK, et al
    Amyloid-beta-activated microglia can induce compound proteinopathies.
    Brain. 2024;147:4105-4120.
    >> Share

    November 2024
  24. DUONG MT, Das SR, Khandelwal P, Lyu X, et al
    Hypometabolic mismatch with atrophy and tau pathology in mixed Alzheimer and Lewy body disease.
    Brain. 2024 Nov 22:awae352. doi: 10.1093.
    >> Share

  25. KOCH G, Altomare D, Benussi A, Brechet L, et al
    The emerging field of non-invasive brain stimulation in Alzheimer's disease.
    Brain. 2024 Nov 20:awae292. doi: 10.1093.
    >> Share

  26. COLLOBY SJ, McAleese KE, Walker L, Erskine D, et al
    Patterns of tau, amyloid and synuclein pathology in ageing, Alzheimer's disease and synucleinopathies.
    Brain. 2024 Nov 12:awae372. doi: 10.1093.
    >> Share

  27. PELKMANS W, Gispert JD
    Astroglial reactivity is a key modulator of Alzheimer's disease pathological progression.
    Brain. 2024 Nov 8:awae354. doi: 10.1093.
    >> Share

  28. MACMULLEN C, Sharma N, Davis RL
    Mitochondrial dynamics and bioenergetics in Alzheimer's induced pluripotent stem cell-derived neurons.
    Brain. 2024 Nov 8:awae364. doi: 10.1093.
    >> Share

  29. DALY T, Imbimbo BP
    Metformin may reduce Alzheimer's disease risk by increasing soluble amyloid-beta42 levels.
    Brain. 2024 Nov 8:awae367. doi: 10.1093.
    >> Share

  30. WELIKOVITCH LA, Mate de Gerando A, Khasnavis A, Bhavsar H, et al
    Tau, synapse loss and gliosis progress in an Alzheimer's mouse model after amyloid-beta immunotherapy.
    Brain. 2024 Nov 6:awae345. doi: 10.1093.
    >> Share

  31. SAKATO Y, Shima A, Terada Y, Takeda K, et al
    Delineating three distinct spatiotemporal patterns of brain atrophy in Parkinson's disease.
    Brain. 2024;147:3702-3713.
    >> Share

  32. BENJAMIN-ZUKERMAN T, Shimon G, Gaine ME, Dakwar A, et al
    A mutation in the PRKAR1B gene drives pathological mechanisms of neurodegeneration across species.
    Brain. 2024;147:3890-3905.
    >> Share

    October 2024
  33. KOVACS GG, Katsumata Y, Wu X, Aung KZ, et al
    Amyloid-beta predominant Alzheimer's disease neuropathologic change.
    Brain. 2024 Oct 17:awae325. doi: 10.1093.
    >> Share

  34. KATSUMI Y, Howe IA, Eckbo R, Wong B, et al
    Default mode network tau predicts future clinical decline in atypical early Alzheimer's disease.
    Brain. 2024 Oct 16:awae327. doi: 10.1093.
    >> Share

  35. AGRAWAL S, Yu L, Leurgans SE, Kapasi A, et al
    Grey matter ageing-related tau astrogliopathy: associations with brain pathologies and cognitive decline.
    Brain. 2024;147:3501-3512.
    >> Share

  36. REUS LM, Jansen IE, Tijms BM, Visser PJ, et al
    Connecting dementia risk loci to the CSF proteome identifies pathophysiological leads for dementia.
    Brain. 2024;147:3522-3533.
    >> Share

    September 2024
  37. ABANTO J, Dwivedi AK, Imbimbo BP, Espay AJ, et al
    Increases in amyloid-beta42 slow cognitive and clinical decline in Alzheimer's disease trials.
    Brain. 2024 Sep 11:awae216. doi: 10.1093.
    >> Share

    August 2024
  38. ZELEK WM, Bevan RJ, Nimmo J, Dewilde M, et al
    Brain-penetrant complement inhibition mitigates neurodegeneration in an Alzheimer's disease mouse model.
    Brain. 2024 Aug 31:awae278. doi: 10.1093.
    >> Share

  39. SHAHIDEHPOUR RK, Nelson PT, Katsumata Y, Bachstetter AD, et al
    Exploring the link between dystrophic microglia and the spread of Alzheimer's neuropathology.
    Brain. 2024 Aug 5:awae258. doi: 10.1093.
    >> Share

  40. GOMEZ-MURCIA V, Launay A, Carvalho K, Burgard A, et al
    Neuronal A2A receptor exacerbates synapse loss and memory deficits in APP/PS1 mice.
    Brain. 2024;147:2691-2705.
    >> Share

    July 2024
  41. YANG Y, Chen H, Huang S, Chen H, et al
    BOK-engaged mitophagy alleviates neuropathology in Alzheimer's disease.
    Brain. 2024 Jul 25:awae241. doi: 10.1093.
    >> Share

  42. MATTSSON-CARLGREN N
    Disentangling genetic risks for development and progression of Alzheimer's disease.
    Brain. 2024 Jul 18:awae237. doi: 10.1093.
    >> Share

  43. RAMANAN S, Akarca D, Henderson SK, Rouse MA, et al
    The graded multidimensional geometry of phenotypic variation and progression in neurodegenerative syndromes.
    Brain. 2024 Jul 17:awae233. doi: 10.1093.
    >> Share

  44. APPLETON J, Finn Q, Zanotti-Fregonara P, Yu M, et al
    Brain inflammation co-localizes highly with tau in mild cognitive impairment due to early-onset Alzheimer's disease.
    Brain. 2024 Jul 16:awae234. doi: 10.1093.
    >> Share

  45. CAI H, Zhao T, Pang Y, Fu X, et al
    Systemic inflammatory markers in ageing, Alzheimer's disease and other dementias.
    Brain. 2024 Jul 15:awae230. doi: 10.1093.
    >> Share

  46. BARBA L, Abu-Rumeileh S, Barthel H, Massa F, et al
    Clinical and diagnostic implications of Alzheimer's disease copathology in Lewy body disease.
    Brain. 2024 Jul 11:awae203. doi: 10.1093.
    >> Share

  47. DEVULDER A, Vanderlinden G, Van Langenhoven L, Testelmans D, et al
    Epileptic activity on foramen ovale electrodes is associated with sleep and tau pathology in Alzheimer's disease.
    Brain. 2024 Jul 11:awae231. doi: 10.1093.
    >> Share

  48. HUSAIN M
    The heterogeneity of Alzheimer's disease.
    Brain. 2024;147:2259-2260.
    >> Share

  49. OKKELS N, Grothe MJ, Taylor JP, Hasselbalch SG, et al
    Cholinergic changes in Lewy body disease: implications for presentation, progression and subtypes.
    Brain. 2024;147:2308-2324.
    >> Share

  50. NILSSON J, Pichet Binette A, Palmqvist S, Brum WS, et al
    Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases.
    Brain. 2024;147:2414-2427.
    >> Share

    June 2024
  51. PERETTI DE, Boccalini C, Ribaldi F, Scheffler M, et al
    Association of glial fibrillary acid protein, Alzheimer's disease pathology and cognitive decline.
    Brain. 2024 Jun 28:awae211. doi: 10.1093.
    >> Share


  52. Correction to: Microbiota from Alzheimer's patients induce deficits in cognition and hippocampal neurogenesis.
    Brain. 2024 Jun 28:awae208. doi: 10.1093.
    >> Share

  53. OLNEY KC, Rabichow BE, Wojtas AM, DeTure M, et al
    Distinct transcriptional alterations distinguish Lewy body disease from Alzheimer's disease.
    Brain. 2024 Jun 25:awae202. doi: 10.1093.
    >> Share

  54. BALLERINI A, Biagioli N, Carbone C, Chiari A, et al
    Late-onset temporal lobe epilepsy: insights from brain atrophy and Alzheimer's disease biomarkers.
    Brain. 2024 Jun 25:awae207. doi: 10.1093.
    >> Share

  55. COOMANS EM, Ossenkoppele R
    The implications of amyloid-beta pathology: only time will tell.
    Brain. 2024;147:1934-1936.
    >> Share

    May 2024
  56. ALTMANN A, Aksman LM, Oxtoby NP, Young A, et al
    Towards cascading genetic risk in Alzheimer's disease.
    Brain. 2024 May 31:awae176. doi: 10.1093.
    >> Share

  57. CHEN F, Zhao J, Meng F, He F, et al
    The vascular contribution of apolipoprotein E to Alzheimer's disease.
    Brain. 2024 May 15:awae156. doi: 10.1093.
    >> Share

  58. SOCH J, Richter A, Kizilirmak JM, Schutze H, et al
    Single-value brain activity scores reflect both severity and risk across the Alzheimer's continuum.
    Brain. 2024 May 14:awae149. doi: 10.1093.
    >> Share

  59. BLUM D, Levi S
    Targeting excitatory:inhibitory network imbalance in Alzheimer's disease.
    Brain. 2024 May 13:awae146. doi: 10.1093.
    >> Share

  60. SANCHEZ-JUAN P, Valeriano-Lorenzo E, Ruiz-Gonzalez A, Pastor AB, et al
    Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles.
    Brain. 2024;147:1667-1679.
    >> Share

  61. DING F, Sun Q, Long C, Rasmussen RN, et al
    Dysregulation of extracellular potassium distinguishes healthy ageing from neurodegeneration.
    Brain. 2024;147:1726-1739.
    >> Share

    April 2024
  62. CODY KA, Langhough RE, Zammit MD, Clark L, et al
    Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease.
    Brain. 2024 Apr 26:awae116. doi: 10.1093.
    >> Share

  63. BARBOUR AJ, Gourmaud S, Lancaster E, Li X, et al
    Seizures exacerbate excitatory: inhibitory imbalance in Alzheimer's disease and 5XFAD mice.
    Brain. 2024 Apr 25:awae126. doi: 10.1093.
    >> Share

  64. BAUMEISTER H, Vogel JW, Insel PS, Kleineidam L, et al
    A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings.
    Brain. 2024 Apr 24:awae118. doi: 10.1093.
    >> Share

  65. LIMBERGER C, Zimmer ER
    Blood GFAP reflects astrocyte reactivity to Alzheimer's pathology in post-mortem brain tissue.
    Brain. 2024 Apr 18:awae104. doi: 10.1093.
    >> Share


  66. Correction to: Disrupted daily activity/rest cycles in relation to daily cortisol rhythms of home-dwelling patients with early Alzheimer's dementia.
    Brain. 2024 Apr 10:awae103. doi: 10.1093.
    >> Share

  67. WANG YT, Therriault J, Servaes S, Tissot C, et al
    Sex-specific modulation of amyloid-beta on tau phosphorylation underlies faster tangle accumulation in females.
    Brain. 2024;147:1497-1510.
    >> Share

  68. TANAKA H, Martinez-Valbuena I, Forrest SL, Couto B, et al
    Distinct involvement of the cranial and spinal nerves in progressive supranuclear palsy.
    Brain. 2024;147:1399-1411.
    >> Share

  69. CORRIVEAU-LECAVALIER N, Barnard LR, Botha H, Graff-Radford J, et al
    Uncovering the distinct macro-scale anatomy of dysexecutive and behavioural degenerative diseases.
    Brain. 2024;147:1483-1496.
    >> Share

    March 2024
  70. HUNG C, Fertan E, Livesey FJ, Klenerman D, et al
    APP antisense oligonucleotides reduce Abeta aggregation and rescue endolysosomal dysfunction in Alzheimer's disease.
    Brain. 2024 Mar 25:awae092. doi: 10.1093.
    >> Share

  71. RODRIGUEZ-RODRIGUEZ P, Arroyo-Garcia LE, Tsagkogianni C, Li L, et al
    A cell autonomous regulator of neuronal excitability modulates tau in Alzheimer's disease vulnerable neurons.
    Brain. 2024 Mar 11:awae051. doi: 10.1093.
    >> Share

  72. RODRIGUEZ-VIEITEZ E, Vannini P, Montal V, Graff C, et al
    Cortical microstructural imaging from diffusion MRI: towards sensitive biomarkers for clinical trials.
    Brain. 2024;147:746-748.
    >> Share

  73. DE MEYER S, Blujdea ER, Schaeverbeke J, Reinartz M, et al
    Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes.
    Brain. 2024;147:936-948.
    >> Share

    February 2024
  74. YANG HS, Yau WW, Carlyle BC, Trombetta BA, et al
    Plasma VEGFA and PGF impact longitudinal tau and cognition in preclinical Alzheimer's disease.
    Brain. 2024 Feb 5:awae034. doi: 10.1093.
    >> Share

  75. AHMED H, Wang Y, Griffiths WJ, Levey AI, et al
    Brain cholesterol and Alzheimer's disease: challenges and opportunities in probe and drug development.
    Brain. 2024 Feb 1:awae028. doi: 10.1093.
    >> Share

  76. ALBERT-GASCO H, Smith HL, Alvarez-Castelao B, Swinden D, et al
    Trazodone rescues dysregulated synaptic and mitochondrial nascent proteomes in prion neurodegeneration.
    Brain. 2024;147:649-664.
    >> Share

    January 2024
  77. KUMAR M, Quittot N, Dujardin S, Schlaffner CN, et al
    Alzheimer proteopathic tau seeds are biochemically a forme fruste of mature paired helical filaments.
    Brain. 2024 Jan 18:awad378. doi: 10.1093.
    >> Share

  78. KIIANITSA K, Lukes ME, Hayes BJ, Brutman J, et al
    TREM2 variants that cause early dementia and increase Alzheimer's disease risk affect gene splicing.
    Brain. 2024 Jan 16:awae014. doi: 10.1093.
    >> Share

  79. HAN Y, Chen K, Zhang B, Yu H, et al
    Maf1 loss regulates spinogenesis and attenuates cognitive impairment in Alzheimer's disease.
    Brain. 2024 Jan 16:awae015. doi: 10.1093.
    >> Share

  80. QIN C, Chen M, Dong MH, Yang S, et al
    Soluble TREM2 triggers microglial dysfunction in neuromyelitis optica spectrum disorders.
    Brain. 2024;147:163-176.
    >> Share

    December 2023
  81. SAMANTA S, Akhter F, Roy A, Chen D, et al
    New cyclophilin D inhibitor rescues mitochondrial and cognitive function in Alzheimer's disease.
    Brain. 2023 Dec 26:awad432. doi: 10.1093.
    >> Share

  82. SPOTORNO N, Strandberg O, Stomrud E, Janelidze S, et al
    Diffusion MRI tracks cortical microstructural changes during the early stages of Alzheimer's disease.
    Brain. 2023 Dec 21:awad428. doi: 10.1093.
    >> Share

  83. STOUFFER KM, Grande X, Duezel E, Johansson M, et al
    Amidst an amygdala renaissance in Alzheimer's disease.
    Brain. 2023 Dec 18:awad411. doi: 10.1093.
    >> Share

  84. YUYAMA K, Sun H, Fujii R, Hemmi I, et al
    Extracellular vesicle proteome unveils cathepsin B connection to Alzheimer's disease pathogenesis.
    Brain. 2023 Dec 10:awad361. doi: 10.1093.
    >> Share

  85. TARUTANI A, Kametani F, Tahira M, Saito Y, et al
    Distinct tau folds initiate templated seeding and alter the post-translational modification profile.
    Brain. 2023;146:4988-4999.
    >> Share

  86. GUBERT C, Hannan AJ
    Microbial manipulation of memories and minds.
    Brain. 2023;146:4791-4793.
    >> Share

    November 2023
  87. QUESNEL MJ, Labonte A, Picard C, Zetterberg H, et al
    Insulin-like growth factor binding protein-2 in at-risk adults and autopsy-confirmed Alzheimer brains.
    Brain. 2023 Nov 22:awad398. doi: 10.1093.
    >> Share

  88. SILVA-RODRIGUEZ J, Labrador-Espinosa MA, Moscoso A, Scholl M, et al
    Characteristics of amnestic patients with hypometabolism patterns suggestive of Lewy body pathology.
    Brain. 2023;146:4520-4531.
    >> Share

  89. HAMPEL H, Elhage A, Cho M, Apostolova LG, et al
    Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics.
    Brain. 2023;146:4414-4424.
    >> Share

  90. RAMANAN VK, Gebre RK, Graff-Radford J, Hofrenning E, et al
    Genetic risk scores enhance the diagnostic value of plasma biomarkers of brain amyloidosis.
    Brain. 2023;146:4508-4519.
    >> Share

    October 2023
  91. GRABRUCKER S, Marizzoni M, Silajdzic E, Lopizzo N, et al
    Microbiota from Alzheimer's patients induce deficits in cognition and hippocampal neurogenesis.
    Brain. 2023 Oct 18:awad303. doi: 10.1093.
    >> Share

  92. TUNOLD JA, Tan MMX, Koga S, Geut H, et al
    Lysosomal polygenic risk is associated with the severity of neuropathology in Lewy body disease.
    Brain. 2023;146:4077-4087.
    >> Share

  93. KEPP KP, Robakis NK, Hoilund-Carlsen PF, Sensi SL, et al
    The amyloid cascade hypothesis: an updated critical review.
    Brain. 2023;146:3969-3990.
    >> Share

  94. DU F, Yu Q, Swerdlow RH, Waites CL, et al
    Glucocorticoid-driven mitochondrial damage stimulates Tau pathology.
    Brain. 2023;146:4378-4394.
    >> Share

    September 2023
  95. COOMANS EM, van Westen D, Pichet Binette A, Strandberg O, et al
    Interactions between vascular burden and amyloid-beta pathology on trajectories of tau accumulation.
    Brain. 2023 Sep 18:awad317. doi: 10.1093.
    >> Share

  96. HARDY J, Mummery C
    Reply: Lecanemab: turning point, or status quo? An ethics perspective.
    Brain. 2023;146:e73.
    >> Share

  97. BOCANCEA DI, Svenningsson AL, van Loenhoud AC, Groot C, et al
    Determinants of cognitive and brain resilience to tau pathology: a longitudinal analysis.
    Brain. 2023;146:3719-3734.
    >> Share

  98. DALY T
    Lecanemab: turning point, or status quo? An ethics perspective.
    Brain. 2023;146:e71-e72.
    >> Share

  99. COOMANS EM, Tomassen J, Ossenkoppele R, Tijms BM, et al
    Genetically identical twin-pair difference models support the amyloid cascade hypothesis.
    Brain. 2023;146:3735-3746.
    >> Share

    August 2023
  100. KERAMIDIS I, McAllister BB, Bourbonnais J, Wang F, et al
    Restoring neuronal chloride extrusion reverses cognitive decline linked to Alzheimer's disease mutations.
    Brain. 2023 Aug 8:awad250. doi: 10.1093.
    >> Share

  101. JUNG Y, Damoiseaux JS
    The potential of blood neurofilament light as a marker of neurodegeneration for Alzheimer's disease.
    Brain. 2023 Aug 4:awad267. doi: 10.1093.
    >> Share

  102. WUESTEFELD A, Pichet Binette A, Berron D, Spotorno N, et al
    Age-related and amyloid-beta-independent tau deposition and its downstream effects.
    Brain. 2023;146:3192-3205.
    >> Share

  103. RAHAYEL S, Tremblay C, Vo A, Misic B, et al
    Mitochondrial function-associated genes underlie cortical atrophy in prodromal synucleinopathies.
    Brain. 2023;146:3301-3318.
    >> Share

  104. MCMILLAN PJ, Benbow SJ, Uhrich R, Saxton A, et al
    Tau-RNA complexes inhibit microtubule polymerization and drive disease-relevant conformation change.
    Brain. 2023;146:3206-3220.
    >> Share

    July 2023
  105. GARCIA AM, de Leon J, Tee BL, Blasi DE, et al
    Speech and language markers of neurodegeneration: a call for global equity.
    Brain. 2023 Jul 27:awad253. doi: 10.1093.
    >> Share

  106. AKSMAN LM, Oxtoby NP, Scelsi MA, Wijeratne PA, et al
    A data-driven study of Alzheimer's disease related amyloid and tau pathology progression.
    Brain. 2023 Jul 11:awad232. doi: 10.1093.
    >> Share

  107. YOUNG AL, Vogel JW, Robinson JL, McMillan CT, et al
    Data-driven neuropathological staging and subtyping of TDP-43 proteinopathies.
    Brain. 2023;146:2975-2988.
    >> Share

    June 2023

  108. Correction to: Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration.
    Brain. 2023 Jun 27:awad208. doi: 10.1093.
    >> Share

  109. VAN DER ENDE EL, In 't Veld SGJG, Hanskamp I, van der Lee S, et al
    CSF proteomics in autosomal dominant Alzheimer's disease highlights parallels with sporadic disease.
    Brain. 2023 Jun 22:awad213. doi: 10.1093.
    >> Share

  110. BANERJEE G, Collinge J, Fox NC, Lashley T, et al
    Clinical considerations in early-onset cerebral amyloid angiopathy.
    Brain. 2023 Jun 6:awad193. doi: 10.1093.
    >> Share

  111. SCHOONHOVEN DN, Coomans EM, Millan AP, van Nifterick AM, et al
    Tau protein spreads through functionally connected neurons in Alzheimer's disease: a combined MEG/PET study.
    Brain. 2023 Jun 5:awad189. doi: 10.1093.
    >> Share


  112. Correction: The most valuable player or the tombstone: is tau the correct target to treat Alzheimer's disease?
    Brain. 2023 Jun 1:awad176. doi: 10.1093.
    >> Share

  113. EDWARDS HM, Wallace CE, Gardiner WD, Doherty BM, et al
    Sex-dependent effects of acute stress on amyloid-beta in male and female mice.
    Brain. 2023;146:2268-2274.
    >> Share

  114. ROBINSON JL, Xie SX, Baer DR, Suh E, et al
    Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated.
    Brain. 2023;146:2557-2569.
    >> Share

    May 2023
  115. ZHU M, Xiao B, Xue T, Qin S, et al
    Cdc42GAP deficiency contributes to the Alzheimer's disease phenotype.
    Brain. 2023 May 31:awad184. doi: 10.1093.
    >> Share

  116. DAS V, Hajduch M
    Randomizing for Alzheimer's disease drug trials should consider the cancer history of participants.
    Brain. 2023 May 27:awad177. doi: 10.1093.
    >> Share

  117. HARDY J, Mummery C
    Reply: Unblinding in the lecanemab trial in Alzheimer's disease.
    Brain. 2023 May 23:awad201. doi: 10.1093.
    >> Share

  118. VAN GOOL WA
    Unblinding in the lecanemab trial in Alzheimer's disease.
    Brain. 2023 May 18:awad171. doi: 10.1093.
    >> Share

  119. KORETSKY MJ, Alvarado C, Makarious MB, Vitale D, et al
    Genetic risk factor clustering within and across neurodegenerative diseases.
    Brain. 2023 May 16:awad161. doi: 10.1093.
    >> Share

  120. JIANG J, Johnson JCS, Requena-Komuro MC, Benhamou E, et al
    Comprehension of acoustically degraded speech in Alzheimer's disease and primary progressive aphasia.
    Brain. 2023 May 15:awad163. doi: 10.1093.
    >> Share

  121. YOUNES K, Sha SJ
    The MVP or the tombstone: is tau the correct target to treat Alzheimer's disease?
    Brain. 2023 May 8:awad151. doi: 10.1093.
    >> Share

    April 2023
  122. GOSSYE H, Van Mossevelde S, Sieben A, Bjerke M, et al
    Patients carrying the mutation p.R406W in MAPT present with non-conforming phenotypic spectrum.
    Brain. 2023;146:1624-1636.
    >> Share

  123. PONNUSAMY M, Wang S, Yuksel M, Hansen MT, et al
    Loss of forebrain BIN1 attenuates hippocampal pathology and neuroinflammation in a tauopathy model.
    Brain. 2023;146:1561-1579.
    >> Share

  124. NAM MH, Ko HY, Kim D, Lee S, et al
    Visualizing reactive astrocyte-neuron interaction in Alzheimer's disease using 11C-acetate and 18F-FDG.
    Brain. 2023 Apr 17:awad037. doi: 10.1093.
    >> Share

  125. MATTSSON-CARLGREN N, Palmqvist S
    The emerging era of staging Alzheimer's disease pathology using plasma biomarkers.
    Brain. 2023 Apr 6:awad112. doi: 10.1093.
    >> Share

    March 2023

  126. Correction to: Blood-brain barrier opening of the default mode network in Alzheimer's disease with magnetic resonance-guided focused ultrasound.
    Brain. 2023 Mar 22:awad082. doi: 10.1093.
    >> Share

  127. DONADIO V, Incensi A, Rizzo G, Westermark GT, et al
    Phosphorylated alpha-synuclein in skin Schwann cells: a new biomarker for multiple system atrophy.
    Brain. 2023;146:1065-1074.
    >> Share

  128. GREVE HJ, Dunbar AL, Lombo CG, Ahmed C, et al
    The bidirectional lung brain-axis of amyloid-beta pathology: ozone dysregulates the peri-plaque microenvironment.
    Brain. 2023;146:991-1005.
    >> Share

    February 2023
  129. JACK CR, Wiste HJ, Algeciras-Schimnich A, Figdore DJ, et al
    Predicting amyloid PET and tau PET stages with plasma biomarkers.
    Brain. 2023 Feb 15:awad042. doi: 10.1093.
    >> Share

    September 2022
  130. GROOT C, Smith R, Stomrud E, Binette AP, et al
    Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals.
    Brain. 2022 Sep 9. pii: 6695020. doi: 10.1093.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016